NeuroDerm says Parkinson's drug shows promise in study

(Reuters) - NeuroDerm Ltd said data from a mid-stage study suggested that a higher dose of its Parkinson's drug could provide an alternative to treatments that require surgery, sending its shares soaring 34 percent premarket.

from

• غرد
• مشاركة
• إضافة